Poor Risk Advanced Renal Cell Carcinoma: Outcomes from a Registry in a Tertiary Cancer Center.

about

Poor Risk Advanced Renal Cell Carcinoma: Outcomes from a Registry in a Tertiary Cancer Center.

Item

http://www.wikidata.org/entity/Q47147905

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Poor Risk Advanced Renal Cell ...... y in a Tertiary Cancer Center.

@en

Poor Risk Advanced Renal Cell ...... y in a Tertiary Cancer Center.

@nl

type

Item

label

Poor Risk Advanced Renal Cell ...... y in a Tertiary Cancer Center.

@en

Poor Risk Advanced Renal Cell ...... y in a Tertiary Cancer Center.

@nl

prefLabel

Poor Risk Advanced Renal Cell ...... y in a Tertiary Cancer Center.

@en

Poor Risk Advanced Renal Cell ...... y in a Tertiary Cancer Center.

@nl

P1476

Poor Risk Advanced Renal Cell ...... y in a Tertiary Cancer Center.

@en

P2093

Amit Joshi

http://www.w3.org/2001/XMLSchema#string

Anant Ramaswamy

http://www.w3.org/2001/XMLSchema#string

Archi Agrawal

http://www.w3.org/2001/XMLSchema#string

Arvind Sahu

http://www.w3.org/2001/XMLSchema#string

Deepan R Manickam

http://www.w3.org/2001/XMLSchema#string

Kumar Prabhash

http://www.w3.org/2001/XMLSchema#string

Nilesh Sable

http://www.w3.org/2001/XMLSchema#string

Rushabh Kothari

http://www.w3.org/2001/XMLSchema#string

Santosh Menon

http://www.w3.org/2001/XMLSchema#string

Vanita Noronha

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.

P304

311-315

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/IJMPO.IJMPO_154_16

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29200680

http://www.w3.org/2001/XMLSchema#string

P932

5686973

http://www.w3.org/2001/XMLSchema#string